secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001787306-24-000151
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M
-----------------------------------------------------------------

- ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.
- Net loss $41.5M ($0.33/sh) vs $44.8M ($0.73/sh) in Q3 '23; operating cash burn improved 23% QoQ to $34.7M.
- Blended gross-to-net improved to low 50% range from high 50% last quarter; approaching steady state for foam.
- Amended $200M SLR loan: lower rate, maturity extended to Aug '29; prepaid $100M on Oct 8, 2024.
- sNDA for ZORYVE foam in scalp/body psoriasis accepted; PDUFA May 22, 2025. Health Canada approval for foam in SD received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/0001787306-24-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/arqt-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer